Metrics as of 10/15/2026, 09:26 PM (Berlin time), refresh in progress.
CelLBxHealth Stock
CelLBxHealth plc
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United Kingdom
- CEO
- Peter Michael Collins
- Employees
- 114
- Market cap
- £9 M
- IPO
- 17/03/2004
CelLBxHealth plc is a medical diagnostics firm specializing in the creation of cancer detection solutions, with operations spanning the United Kingdom, broader Europe, North America, and other global markets. A flagship offering is the Parsortix PC1 system, a medical device engineered to isolate and collect whole…
CelLBxHealth stock: price history
1D
-2.9%
1W
-2.9%
1M
-23.6%
6M
-8.3%
YTD
-25.0%
1Y
-56.6%
2Y
-89.4%
5Y
-99.3%
10Y
-98.8%
Next earnings date
Next earnings date
29/04/2027 (in 194 days)
Volatility around earnings
~100% stronger price swings than usual
Ask the agents about CelLBxHealth
Free float & liquidity
FREE FLOAT
11.0%
FLOAT SHARES
124,795,357
AVG. DAILY VOLUME (30D)
2,122,632
Dividends & Stock splits
Comparable stocks
Frequently asked questions about CelLBxHealth stock
What does CelLBxHealth do?
CelLBxHealth plc is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United Kingdom.
The CEO is Peter Michael Collins, the company employs around 114 people.
The IPO was on 17/03/2004; the stock trades on LSE under the ticker CLBX.L.
When does CelLBxHealth report next?
The next earnings date is 29/04/2027.
Around past earnings, price swings were roughly 100% stronger than usual.
Does CelLBxHealth pay a dividend?
No, CelLBxHealth currently does not pay a dividend.
Which stocks are comparable to CelLBxHealth?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get CelLBxHealth stock analyzed?
Clicking "Analyze stock" lets five strategies assess CelLBxHealth against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.